AGIOS PHARMACEUTICALS, INC. Income Taxes Paid
AGIOS PHARMACEUTICALS, INC. (AGIO) reported Income Taxes Paid of $43.15 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-13.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:IncomeTaxesPaid · last filed 2025-02-13
- AGIOS PHARMACEUTICALS, INC. income taxes paid for the quarter ending 2023-12-31 was -$17.00K.
- AGIOS PHARMACEUTICALS, INC. income taxes paid for the quarter ending 2023-09-30 was $785.00K, a 701.02% increase year-over-year.
- AGIOS PHARMACEUTICALS, INC. income taxes paid for the quarter ending 2023-06-30 was $801.00K.
- AGIOS PHARMACEUTICALS, INC. income taxes paid for the quarter ending 2023-03-31 was $0.00, a 100.00% decline year-over-year.
- AGIOS PHARMACEUTICALS, INC. income taxes paid for fiscal 2024 was $43.15M, a 2650.16% increase from fiscal 2023.
- AGIOS PHARMACEUTICALS, INC. income taxes paid for fiscal 2023 was $1.57M.
- AGIOS PHARMACEUTICALS, INC. income taxes paid for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- AGIOS PHARMACEUTICALS, INC. income taxes paid for fiscal 2021 was $16.08M.
| Period end | Income Taxes Paid 1 month | Income Taxes Paid 1 month as first filed | Income Taxes Paid 3 month | Income Taxes Paid 6 month | Income Taxes Paid 6 month as first filed | Income Taxes Paid 9 month | Income Taxes Paid 9 month as first filed | Income Taxes Paid 12 month |
|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | $43.15M 10-K · filed 2025-02-13 | |||||||
| 2023-12-31 | -$17.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-13 | $768.00K derived: sum of 2 quarters · filed 2025-02-13 | $1.57M derived: sum of 3 quarters · filed 2025-02-13 | $1.57M 10-K · filed 2025-02-13 | ||||
| 2023-09-30 | $785.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $1.59M derived: sum of 2 quarters · filed 2023-11-02 | $1.59M 10-Q · filed 2023-11-02 | -$354.00K derived: sum of 4 quarters · filed 2025-02-13 | ||||
| 2023-06-30 | $801.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $801.00K 10-Q · filed 2023-08-03 | -$1.14M derived: sum of 3 quarters · filed 2025-02-13 | -$1.04M derived: sum of 4 quarters · filed 2025-02-13 | ||||
| 2023-03-31 | $0.00 10-Q · filed 2023-05-04 | -$1.94M derived: sum of 2 quarters · filed 2025-02-13 | -$1.84M derived: sum of 3 quarters · filed 2025-02-13 | -$1.84M derived: sum of 4 quarters · filed 2025-02-13 | ||||
| 2022-12-31 | -$1.94M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-13 | -$1.84M derived: sum of 2 quarters · filed 2025-02-13 | -$1.84M derived: sum of 3 quarters · filed 2025-02-13 | $0.00 10-K · filed 2025-02-13 | ||||
| 2022-09-30 | $98.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $98.00K derived: sum of 2 quarters · filed 2023-11-02 | $1.94M 10-Q · filed 2023-11-02 | $1.90M 10-Q · filed 2022-11-03 | $9.12M derived: sum of 4 quarters · filed 2024-02-15 | |||
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $1.84M 10-Q · filed 2023-08-03 | $1.80M 10-Q · filed 2022-08-04 | $9.02M derived: sum of 3 quarters · filed 2024-02-15 | $11.72M derived: sum of 4 quarters · filed 2024-02-15 | |||
| 2022-03-31 | $1.84M 10-Q · filed 2023-05-04 | $9.02M derived: sum of 2 quarters · filed 2024-02-15 | $11.72M derived: sum of 3 quarters · filed 2024-02-15 | |||||
| 2021-12-31 | $7.18M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $9.88M derived: sum of 2 quarters · filed 2024-02-15 | $16.08M 10-K · filed 2024-02-15 | |||||
| 2021-09-30 | $2.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $8.90M 10-Q · filed 2022-11-03 | ||||||
| 2021-06-30 | $6.20M 10-Q · filed 2022-08-04 | |||||||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $0.00 derived: sum of 2 quarters · filed 2023-02-23 | $0.00 10-K · filed 2023-02-23 | |||||
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $0.00 10-Q · filed 2021-11-03 | ||||||
| 2020-06-30 | $0.00 10-Q · filed 2021-07-29 | |||||||
| 2019-12-31 | $0.00 10-K · filed 2022-02-24 | |||||||
| 2014-12-31 | $22.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-16 | $22.00K derived: sum of 2 quarters · filed 2017-02-16 | $22.00K derived: sum of 3 quarters · filed 2017-02-16 | $5.98M 10-K · filed 2017-02-16 | ||||
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-06 | $0.00 derived: sum of 2 quarters · filed 2015-11-06 | $5.96M 10-Q · filed 2015-11-06 | |||||
| 2014-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-07 | $5.96M 10-Q · filed 2015-08-07 | ||||||
| 2014-03-31 | $5.96M 10-Q · filed 2015-05-11 | |||||||
| 2014-01-31 | $6.00M 10-Q · filed 2016-11-03 | $5.96M 10-Q · filed 2014-08-07 | ||||||
| 2012-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-24 | $49.00K derived: sum of 2 quarters · filed 2015-02-24 | $3.55M 10-K · filed 2015-02-24 | |||||
| 2012-09-30 | $49.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-07 | $3.55M 10-Q · filed 2013-11-07 | ||||||
| 2012-06-30 | $3.50M 10-Q · filed 2013-09-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |